In vitro and in vivo drug interactions involving human CYP3A.
about
Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitroThe chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genomeAging and the environment: a research frameworkCalcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic InteractionsPharmacokinetic drug interactions in liver disease: An updateRole of reactive metabolites in the circulation in extrahepatic toxicityA novel type of allosteric regulation: functional cooperativity in monomeric proteinsPharmacokinetic drug-drug interaction and their implication in clinical managementMarine invertebrate xenobiotic-activated nuclear receptors: their application as sensor elements in high-throughput bioassays for marine bioactive compoundsEletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent responseFunctionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping testsVitamin E in human health and diseaseInhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomesInteraction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 PolymorphismGenetic variability in CYP3A5 and its possible consequences.The design of in vitro liver sinusoid mimics using chitosan-hyaluronic acid polyelectrolyte multilayers.Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450.Predicting in vivo drug interactions from in vitro drug discovery data.Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.Pharmacokinetic interactions of drugs with St John's wort.A novel framework for predicting in vivo toxicities from in vitro data using optimal methods for dense and sparse matrix reordering and logistic regression.Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sexEvaluation of amphotericin B and chloramphenicol as alternative drugs for treatment of chytridiomycosis and their impacts on innate skin defenses.3D hepatic cultures simultaneously maintain primary hepatocyte and liver sinusoidal endothelial cell phenotypes.Regulation of cytochrome P450 (CYP) genes by nuclear receptors.Integrated transcriptional and proteomic analysis with in vitro biochemical assay reveal the important role of CYP3A46 in T-2 toxin hydroxylation in porcine primary hepatocytesThe human CYP3A subfamily: practical considerations.A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.A comparative study of genome-wide transcriptional profiles of primary hepatocytes in collagen sandwich and monolayer cultures.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations.The pharmacogenomics of HIV therapy.Cytochromes P450 and experimental models of drug metabolism.Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population.Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation.
P2860
Q24301858-1DA2D385-CED2-4065-9BA6-09ABDDA7AE7EQ24605756-E93C69AB-64E3-41FE-82ED-DF42A61EA1D5Q24815677-EAC813A1-FAB5-4E0F-A621-1447FBDFD4F5Q26766242-BF0B30C8-AFA9-4D6F-8250-0DC9D6686DC3Q26774479-A2EA19D1-9F49-43FC-B5A6-854C8AB41962Q26849288-346789AF-A807-44C6-A533-69A0180FFFE9Q27011182-29129B41-C64F-4155-9A17-F45C85E8DA54Q27021051-020AF830-042F-4874-81B0-F583E707AACAQ27022545-7356A628-DE65-4176-A933-9A96CC6AEDC2Q28074159-FDBB94C6-0D15-451C-B2E2-68AE8514C061Q28260518-25E6F1FF-5088-49D2-A368-D4936D1CF980Q28291248-DE4FD34D-4F60-4081-A649-5739EE56D63BQ28367528-FFC27D39-993B-40F2-8E21-DE66DF70C284Q28552997-0FE376F9-FB11-497A-8444-205057CD7F32Q30341330-5598D82D-9125-4AF7-8618-1B13BC377760Q30474413-8682479F-8E63-4AE1-BDCA-AA8A1FFB4093Q30499595-C00BD19C-4AB8-4243-8C3B-14C97F0FC0E7Q31011412-CF57A442-4AF6-4869-979B-AFBEA02D81F1Q32064655-3C8180F8-EE05-4BB3-89A8-B8F816CEFB0EQ33148910-0A9AC5AA-06EC-4B6B-B9F9-B769FF691A55Q33204911-FBABB8F4-1AAA-4E6C-8047-8177507ED88BQ33655049-4441F19F-10C3-4F81-9F45-A4D4C6247B56Q33683890-3C23E5CA-2750-4DE6-8737-2C4B64FD76A5Q33743364-240190C1-8BC4-4DC5-8B3F-B002F98CBF37Q33754749-EB11C8F7-A1CD-4B2E-9794-F5E2535DE3A4Q33882753-DE59F59C-C933-4A61-A267-0E0EF2F698EEQ33936029-2673E618-6DBD-4853-A1CA-9357D1B7F07BQ34119161-FC5BE4CC-A900-4939-B374-C105DC62524CQ34180397-8E371CAD-C502-4E50-83C7-0F95DB60DF40Q34278794-AC421B54-FCB4-4F01-920E-C51158D9778BQ34334983-040BB4E4-3183-4002-B013-4A4F6CE4BF9AQ34430456-4458C660-D457-4D15-ACBD-580C9CA52A35Q34448305-6F41D9F2-CB5D-4675-AC5E-E51BD0FCF446Q34491448-0569B8C9-1C8F-4C38-BDC2-5F53D8E54598Q34574033-B2094649-36AF-4778-8050-C3E7293E8C0BQ34778084-C2EBA1DA-649C-40CA-A26C-E28BD4FCBD31Q34810573-E054D896-75F1-4D88-B469-DA5FB904A046Q34963630-73A39DD9-AF7B-4AC0-947E-9AF1CC99D118Q35002433-9A2B3806-610E-4388-9F50-3E3B7D9904D9Q35087638-4531E025-24D9-4DAC-B118-3B6502841167
P2860
In vitro and in vivo drug interactions involving human CYP3A.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
In vitro and in vivo drug interactions involving human CYP3A.
@ast
In vitro and in vivo drug interactions involving human CYP3A.
@en
In vitro and in vivo drug interactions involving human CYP3A.
@nl
type
label
In vitro and in vivo drug interactions involving human CYP3A.
@ast
In vitro and in vivo drug interactions involving human CYP3A.
@en
In vitro and in vivo drug interactions involving human CYP3A.
@nl
prefLabel
In vitro and in vivo drug interactions involving human CYP3A.
@ast
In vitro and in vivo drug interactions involving human CYP3A.
@en
In vitro and in vivo drug interactions involving human CYP3A.
@nl
P1476
In vitro and in vivo drug interactions involving human CYP3A.
@en
P2093
Thummel KE
Wilkinson GR
P304
P356
10.1146/ANNUREV.PHARMTOX.38.1.389
P577
1998-01-01T00:00:00Z